%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2020-05-18T09:55:37-04:00
2020-05-18T09:55:40-04:00
2020-05-18T09:55:40-04:00
Adobe InDesign CC 13.1 (Windows)
uuid:67fc0899-3a50-4150-acb0-65340fd35cac
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:533c7491-94e6-fc4b-99a6-aa200634a2dd
proof:pdf
xmp.iid:14fa394e-52bc-be41-8485-437e87c69ee4
xmp.did:414a3118-bba3-6c4c-8536-7ed51945f015
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 13.1 (Windows)
/
2020-05-18T09:55:37-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
12 0 obj
<>
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
39 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 175.68 404.438 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Which is correct regarding combination)-10 ( )]TJ
0 -1.2 Td
[(therapy for patients with methicillin-resistant)-10 ( )]TJ
/T1_1 1 Tf
0 -1.2 Td
(Staphylococcus aureus)Tj
/T1_0 1 Tf
( bacteremia?)Tj
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0 -1.2 Td
[(a. Combination therapy was associated with)-10 ( )]TJ
0 -1.2 Td
[(reduced mortality)92 (.)]TJ
0 -1.2 Td
[(b. Combination therapy was associated with)-10 ( )]TJ
0 -1.2 Td
[(statistically signi\037cant improvement in the)-9.9 ( )]TJ
0 -1.2 Td
(composite study endpoint.)Tj
0 -1.2 Td
[(c. Combination therapy was associated with)-10 ( )]TJ
0 -1.2 Td
[(a signi\037cantly increased risk of kidney injury)92 (.)]TJ
0 -1.2 Td
[(d. The use of cefazolin was associated with)-10 ( )]TJ
0 -1.2 Td
[(a higher risk of acute kidney injury than was)-10 ( )]TJ
0 -1.2 Td
(the use of an antistaphylococcal penicillin.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Based on the results of the study by Deyle et)-10 ( )]TJ
0 -1.2 Td
(al, which statement is true?)Tj
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0 -1.2 Td
[(a. Patients received the same bene\037t)-10 ( )]TJ
0 -1.2 Td
[(with physical therapy compared with)-10 ( )]TJ
0 -1.2 Td
(glucocorticoid injections.)Tj
0 -1.2 Td
[(b. Patients received a greater bene\037t with)-10 ( )]TJ
0 -1.2 Td
[(glucocorticoid injections compared with)-10 ( )]TJ
0 -1.2 Td
[(physical therapy)92 (.)]TJ
0 -1.2 Td
[(c. Patients received a greater bene\037t)-10 ( )]TJ
0 -1.2 Td
[(with physical therapy compared with)-10 ( )]TJ
0 -1.2 Td
(glucocorticoid injections.)Tj
0 -1.2 Td
[(d. Patients received no bene\037t with physical)-10 ( )]TJ
0 -1.2 Td
(therapy or glucocorticoid injections.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
20.958 31.694 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In a large, community-based study)92 (, subjects)-10 ( )]TJ
0 -1.2 Td
[(who developed heart failure also had a higher)-10 ( )]TJ
0 -1.2 Td
(risk of:)Tj
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0 -1.2 Td
(a. pneumonia.)Tj
0 -1.2 Td
(b. deep venous thrombosis.)Tj
0 -1.2 Td
(c. stroke.)Tj
0 -1.2 Td
(d. peripheral vascular disease.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-1.588 -2.894 Td
(4.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The relationship between hormonal therapy)-10 ( )]TJ
0 -1.2 Td
[(and Alzheimer\222)92 (s disease \(AD\) that appears)-9.9 ( )]TJ
0 -1.2 Td
[(most consistent across studies is that:)-10 ( )]TJ
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
0 -1.2 Td
[(a. a short duration of therapy \(< 3 years\))-10 ( )]TJ
0 -1.2 Td
[(provides the maximum protection against)-10 ( )]TJ
0 -1.2 Td
(development of AD.)Tj
0 -1.2 Td
[(b. a long duration of therapy \(> 10 years\))-10 ( )]TJ
0 -1.2 Td
[(provides the maximum protection against)-10 ( )]TJ
0 -1.2 Td
(development of AD.)Tj
0 -1.2 Td
[(c. a short duration of therapy \(< 3 years\))-10 ( )]TJ
0 -1.2 Td
(increases the risk of development of AD.)Tj
0 -1.2 Td
[(d. a long duration of therapy \(> 10 years\))-10 ( )]TJ
0 -1.2 Td
[(increases the risk of development of AD.)-10 ( )]TJ
ET
0 0 0 0.2 K
13 w
/GS0 gs
q 1 0 0 1 253.3886 661.8799 cm
0 0 m
81.649 0 l
S
Q
q 1 0 0 1 164.8495 649.8799 cm
0 0 m
161.159 0 l
S
Q
q 1 0 0 1 164.8495 637.8799 cm
0 0 m
168.867 0 l
S
Q
q 1 0 0 1 164.8495 625.8799 cm
0 0 m
176.078 0 l
S
Q
q 1 0 0 1 164.8495 613.8799 cm
0 0 m
175.029 0 l
S
Q
q 1 0 0 1 164.8495 601.8799 cm
0 0 m
109.999 0 l
S
Q
q 1 0 0 1 274.8483 602.46 cm
0 0 m
3.241 0 l
S
Q
q 1 0 0 1 278.0898 601.8799 cm
0 0 m
53.899 0 l
S
Q
q 1 0 0 1 164.8495 589.8799 cm
0 0 m
155.019 0 l
S
Q
q 1 0 0 1 164.8495 577.8799 cm
0 0 m
184.418 0 l
S
Q
q 1 0 0 1 164.8495 565.8799 cm
0 0 m
180.018 0 l
S
Q
q 1 0 0 1 164.8495 553.8799 cm
0 0 m
184.339 0 l
S
Q
q 1 0 0 1 349.1885 557.21 cm
0 0 m
3.241 0 l
S
Q
q 1 0 0 1 352.43 553.8799 cm
0 0 m
1.907 0 l
S
Q
q 1 0 0 1 164.8495 541.8799 cm
0 0 m
189.488 0 l
S
Q
q 1 0 0 1 164.8495 529.8799 cm
0 0 m
170.059 0 l
S
Q
q 1 0 0 1 164.8495 517.8799 cm
0 0 m
187.808 0 l
S
Q
q 1 0 0 1 164.8495 505.8799 cm
0 0 m
189.488 0 l
S
Q
q 1 0 0 1 164.8495 493.8799 cm
0 0 m
161.179 0 l
S
Q
BT
/GS1 gs
0 Tc 10 0 0 10 164.8495 730.8799 Tm
(improves overall survival \(56.5 months vs. )Tj
0 -1.2 Td
(48 months for trastuzmab and docetaxel )Tj
0 -1.2 Td
(plus placebo\).)Tj
5.83 0 0 5.83 224.869 710.21 Tm
(4)Tj
10 0 0 10 228.1105 706.8799 Tm
( This improvement was )Tj
-6.326 -1.2 Td
[(maintained after an additional four)55.1 (-)]TJ
0 -1.2 Td
(year follow-up.)Tj
5.83 0 0 5.83 230.9791 686.21 Tm
(5)Tj
10 0 0 10 234.2206 682.8799 Tm
( For those with disease )Tj
-6.937 -1.2 Td
(progression, trastuzumab emtansine is )Tj
0 -1.2 Td
[(second-line therapy)92.1 (. )]TJ
(This improvement )Tj
0 -1.2 Td
(in survival increases the risk of brain )Tj
0 -1.2 Td
(metastases. Breast cancer is the second )Tj
0 -1.2 Td
(most common cause of brain metastases )Tj
0 -1.2 Td
[(after lung cancer)111.1 (, as 15-30% of patients )]TJ
0 -1.2 Td
(develop brain metastases.)Tj
5.83 0 0 5.83 274.8483 602.21 Tm
(6)Tj
10 0 0 10 278.0898 598.8799 Tm
( There is no )Tj
-11.324 -1.2 Td
(standard regimen for treating brain )Tj
0 -1.2 Td
(metastases. The usual treatment is surgery )Tj
0 -1.2 Td
(with postoperative radiation, stereotactic )Tj
0 -1.2 Td
[(radiotherapy)92 (, or whole brain radiotherapy)92.1 (.)]TJ
5.83 0 0 5.83 349.1885 554.21 Tm
(6)Tj
10 0 0 10 352.43 550.8799 Tm
( )Tj
-18.758 -1.2 Td
[(T)86 (ucatinib in combination with trastuzumab )]TJ
0 -1.2 Td
(and capecitabine provides an option in )Tj
0 -1.2 Td
(heavily pretreated patients, including those )Tj
0 -1.2 Td
(with brain metastases. The cost of a 30-day )Tj
0 -1.2 Td
(supply at 600 mg per day is $18,500.)Tj
( )Tj
/C2_0 1 Tf
/Span<>> BDC
<0084>Tj
EMC
/TT0 1 Tf
0.01 Tc -0.01 Tw 9.25 0 0 9.25 367.837 731.5721 Tm
(REFERENCES)Tj
/TT1 1 Tf
-0.025 Tc 0 Tw 0 -1.189 Td
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(U.S. F)35.8 (ood and Drug Administration. FD)17.7 (A approves)-25.1 ( )]TJ
0 -1.189 Td
[(first new drug under international collaboration, a)-25.1 ( )]TJ
0 -1.189 Td
[(treatment option for patients with HER2-positive)-25 ( )]TJ
0 -1.189 Td
[(metastatic breast cancer)100.5 (. April 17, 2020.)-24.9 ( )]TJ
0 Tc 14.523 0 Td
( )Tj
-0.025 Tc 0.025 Tw -14.523 -1.189 Td
(https://bit.ly/3dsbRB8)Tj
0 Tw -1.946 -1.189 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Seattle Genetics. T)169.9 (ukysa P)35.7 (rescribing Information.)-24.9 ( )]TJ
0 -1.189 Td
(April 2020. https://bit.ly/3boT7kx)Tj
-1.946 -1.189 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Murthy RK, L)17.4 (oi S, Okines A, et al. T)169.9 (ucatinib,)-25 ( )]TJ
0 -1.189 Td
[(trastuzumab, and capecitabine for HER2-positive)-25 ( )]TJ
0 -1.189 Td
[(metastatic breast cancer)100.5 (. )]TJ
/TT2 1 Tf
(N Engl J Med)Tj
/TT1 1 Tf
( 2020;382:)Tj
0 Tc 17.565 0 Td
( )Tj
-0.025 Tc 0.025 Tw -17.565 -1.189 Td
[(597-609.)-24.9 ( )]TJ
0 Tw -1.946 -1.189 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Swain SM, Baselga J, Kim SB, et al. P)54.7 (ertuzumab,)-24.9 ( )]TJ
0 -1.189 Td
[(trastuzumab, and docetaxel in HER2-positive)-25 ( )]TJ
0 -1.189 Td
[(metastatic breast cancer)100.5 (. )]TJ
/TT2 1 Tf
(N Engl J Med)Tj
/TT1 1 Tf
( 2015;372:)Tj
0 Tc 17.565 0 Td
( )Tj
-0.025 Tc 0.025 Tw -17.565 -1.189 Td
(724-734.)Tj
0 Tw -1.946 -1.189 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(Helwick C. CLEOP)54.8 (A)91.8 (TRA end-)-18.6 (of-study analysis in)-24.8 ( )]TJ
0 -1.189 Td
(metastatic breast cancer: 37% alive at 8 years. )Tj
/TT2 1 Tf
0.025 Tw [(The)-25 ( )]TJ
0 Tw 0 -1.189 Td
[(ASCO P)54.7 (ost)]TJ
/TT1 1 Tf
(, July 10, 2019. https://bit.ly/2Wqmzm9)Tj
-1.946 -1.189 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.946 0 Td
[(W)17.8 (itzel I, Oliveira-F)35.9 (errer L, P)54.8 (antel K, et al. Breast)-25.2 ( )]TJ
0 -1.189 Td
[(cancer brain metastases: Biology and new clinical)-25.2 ( )]TJ
0.025 Tw 0 -1.189 Td
(perspectives. )Tj
/TT2 1 Tf
0 Tw 4.863 0 Td
(Breast Cancer Res)Tj
/TT1 1 Tf
[( 2016;18:8.)-24.9 ( )]TJ
ET
endstream
endobj
40 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 119.52 120.33 636.48 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 Td
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 Td
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 Td
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
0 -1.143 Td
(reprints@reliasmedia.com.)Tj
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
0 -1.143 Td
(copies, site licenses, or electronic distribution. For pricing )Tj
0 -1.143 Td
(information, please contact our Group Account Managers )Tj
0 -1.143 Td
(at groups@reliasmedia.com or \(866\) 213-0844.)Tj
19.248 0 Td
( )Tj
5.969 3.429 Td
[(T)175 (o reproduce any part of R)17.6 (elias Media newsletters for )]TJ
0 -1.143 Td
(educational purposes, please contact The Copyright )Tj
0 -1.143 Td
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 Td
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
164.911 424.306 392.414 18.174 re
f
0.25 w
164.975 119.645 392.225 305.03 re
S
BT
0 scn
0.037 Tc -0.012 Tw 10 0 0 10 320.3567 430.5355 Tm
[(C)-3.7 (M)-3 (E)12 ( Q)1.9 (U)-3.3 (E)5.9 (S)4.8 (T)10.1 (ION)-11.3 (S)]TJ
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
0 Tc 0 Tw 6 0 0 6 25.2 744.168 Tm
(PHYSICIAN EDITOR)Tj
/TT0 1 Tf
0 -1.167 Td
(Stephen A. Brunton, MD)Tj
/TT1 1 Tf
-0.025 Tc 0 -1.167 Td
[(Adjunct P)35.6 (rofessor of Pharmacy P)35.7 (ractice)]TJ
0 -1.167 Td
(College of Pharmacy)Tj
0 Tc 7.469 0 Td
( )Tj
-0.025 Tc -7.469 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.998 0 Td
( )Tj
-0.025 Tc -13.998 -1.167 Td
[(Salt L)17.4 (ake City)]TJ
/T1_0 1 Tf
0 Tc 0 -2.667 Td
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.167 Td
[(Gerald R)17.7 (oberts, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
(Senior Attending Physician )Tj
( )Tj
0 -1.167 Td
[(L)17.4 (ong Island Jewish Medical Center)]TJ
13.107 0 Td
( )Tj
-13.107 -1.167 Td
(NS/LIJ Health Care System)Tj
10.378 0 Td
( )Tj
-10.378 -1.167 Td
[(New Hyde P)54.8 (ark, NY)]TJ
/T1_0 1 Tf
0 -2.333 Td
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.167 Td
(James Chan, PharmD, PhD)Tj
/TT1 1 Tf
0 -1.167 Td
[(Associate Clinical P)34.4 (rofessor)]TJ
( )Tj
0 -1.167 Td
(School of Pharmacy)Tj
7.563 0 Td
( )Tj
-7.563 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
[(William T)156.1 (. Elliott, MD, F)36.2 (A)17.5 (CP)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Assistant Clinical P)33.9 (rofessor of Medicine )]TJ
0 -1.167 Td
(University of California)Tj
8.642 0 Td
( )Tj
-8.642 -1.167 Td
[(San F)54.9 (rancisco)]TJ
/TT0 1 Tf
0 -1.917 Td
(David Fiore, MD)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor of F)35.9 (amily Medicine)]TJ
0 -1.167 Td
(University of Nevada)Tj
( )Tj
0 -1.167 Td
[(R)17.5 (eno)]TJ
/TT0 1 Tf
0 -1.917 Td
[(K)17.7 (en Grauer)100.9 (, MD)]TJ
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor Emeritus in F)35.1 (amily )]TJ
( )Tj
0 -1.167 Td
(Medicine, College of Medicine,)Tj
0 -1.167 Td
(University of Florida)Tj
0 -1.167 Td
(Gainesville)Tj
/TT0 1 Tf
0 -1.917 Td
(Seema Gupta, MD, MSPH)Tj
/TT1 1 Tf
0 -1.167 Td
[(Clinical Assistant P)33.9 (rofessor)]TJ
0 -1.167 Td
[(Department of F)35.5 (amily )]TJ
( )Tj
0 -1.167 Td
(and Community Health)Tj
( )Tj
0 -1.167 Td
(Joan C. Edwards School of Medicine)Tj
0 -1.167 Td
(Marshall University)Tj
0 -1.167 Td
(Huntington, WV)Tj
/TT0 1 Tf
0 -1.917 Td
[(Martin S. Lipsky)87.5 (, MD)]TJ
/TT1 1 Tf
-0.03 Tc 0.03 Tw 0 -1.167 Td
(Chancellor)Tj
0 Tc 0 Tw 3.889 0 Td
( )Tj
-0.03 Tc -3.889 -1.167 Td
(South Jordan Campus)Tj
0 Tc 7.847 0 Td
( )Tj
-0.03 Tc -7.847 -1.167 Td
[(R)17.5 (oseman University of Health Sciences)]TJ
0 Tc 13.818 0 Td
( )Tj
-0.03 Tc -13.818 -1.167 Td
(South Jordan, UT)Tj
/TT0 1 Tf
0 Tc 0 -1.917 Td
[(Joseph E. Scherger)101.6 (, MD, MPH)]TJ
/TT1 1 Tf
0 -1.167 Td
[(Core F)35.8 (aculty)]TJ
0 -1.167 Td
[(Eisenhower Health F)35.5 (amily Medicine )]TJ
13.922 0 Td
( )Tj
-13.922 -1.167 Td
[(R)17.5 (esidency P)35.5 (rogram)]TJ
0 -1.167 Td
[(Eisenhower Health Center)99.9 (, L)17.5 (a Quinta, CA)]TJ
0 -1.167 Td
[(Clinical P)34.8 (rofessor)]TJ
0 -1.167 Td
[(K)17.6 (eck School of Medicine)]TJ
0 -1.167 Td
(University of Southern California)Tj
12.409 0 Td
( )Tj
-12.409 -1.167 Td
[(L)17.4 (os Angeles)]TJ
/TT0 1 Tf
0 -1.917 Td
(Allan J. Wilke, MD, MA)Tj
/TT1 1 Tf
0 -1.167 Td
[(P)35.7 (rofessor and Chair)]TJ
7.542 0 Td
( )Tj
-7.542 -1.167 Td
[(Department of F)35.5 (amily Medicine)]TJ
12.045 0 Td
( )Tj
-12.045 -1.167 Td
[(W)54.9 (estern Michigan University)]TJ
10.92 0 Td
( )Tj
-10.92 -1.167 Td
(School of Medicine)Tj
( )Tj
0 -1.167 Td
[(K)17.6 (alamazoo)]TJ
/T1_0 1 Tf
-0.01 Tc 0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jonathan Springston)Tj
/T1_0 1 Tf
0.01 Tw 0 -2.5 Td
(EDITOR)Tj
/TT0 1 Tf
0 Tw 0 -1.25 Td
(Jason Schneider)Tj
/T1_0 1 Tf
0 -2.5 Td
(EDITORIAL GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.333 Td
(Leslie Coplin)Tj
/T1_0 1 Tf
0 -2.667 Td
[(ACCREDIT)74 (A)74 (TIONS DIRECTOR)]TJ
/TT0 1 Tf
0 -1.25 Td
(Amy M. Johnson, MSN, RN, CPN)Tj
ET
endstream
endobj
41 0 obj
<>
endobj
42 0 obj
<>
endobj
43 0 obj
<>
endobj
48 0 obj
<>
endobj
49 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
50 0 obj
<>stream
HtV TT[GMf2 QK
YPA%-jpq1XJNkhh5FJکǐ3Ӝ}};G3Hsh|^I^ٕ\@XN:\X9xC@$wg3,d+
rR=i~$7ܷrn$_ʙey9ß f8fy:+*'MiNIv.de ~0a7*0s| <ٕ5ѽrHL
dIE_rqeyI>jzvC"IQ;}GF^%YSS
}CE?2j@!70~!C<3_=ro.}{koܼuݶ{t43Xal"as;5afNI>]Aǜ!1>^ai,bSWug7&8c936ba۩?$nϢU{т]{-7mCs4`Gg^tE~(Ӱ~5h1{QX*|=%N]Re7?)$Y%9E rEs HeGVdKWPs\Ǯ@Q&gE.碜g-CÎQ,8x]O osPOsk2gZlpb-tBBXLj&35S͇r[X6a*$!^vZ#P6y>jD >`ϥ`dӮ=E;2hUPeuSuH3ID"5J::ߒ4!Csf6*WF)k,HS3@qE
o-c{T=YGf bI?rD&&$ә.#(Cx Sy\hSkV[UjUZ
>öIo,)> b([WACr.?[wG>_N=Y